AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14625708 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (ISO group; n = 20)
Number of subjects: 40
Study 14625708 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (SEV group; n = 20)
Number of subjects: 40
Study 14625708 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane and Sevoflurane (both groups)
Number of subjects: 40
Study 11122842 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation
Number of subjects: 0
Study 11122842 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative preparative regimens
Number of subjects: 0
Study 9494591 — intervention group
Group type: COMPARATOR
Intervention: Goserelin alone
Number of subjects: 67
Study 9494591 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin plus mitomycin C
Number of subjects: 67
Study 9494591 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Goserelin alone and Goserelin plus mitomycin C)
Number of subjects: 67
Study 8182270 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 units iHAV i.m. at 0 and 24 weeks
Number of subjects: 75
Study 8182270 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of 25 units iHAV i.m. given 1 or 2 months after primary immunization
Number of subjects: 75
Study 8182270 — intervention group
Group type: COMPARATOR
Intervention: 0.06 ml/kg IG i.m. given once
Number of subjects: 75
Study 3001523 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 22
Study 3001523 — intervention group
Group type: COMPARATOR
Intervention: Vidarabine
Number of subjects: 22
Study 29624887 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-8500a 75 mg
Number of subjects: 21
Study 29624887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29703262 — intervention group
Group type: EXPERIMENTAL
Intervention: Migalastat 150 mg every other day
Number of subjects: 50
Study 29703262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 27107523 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of hyperbaric bupivacaine 0.25% plus 1mL of sufentanil
Number of subjects: 50
Study 27107523 — intervention group
Group type: COMPARATOR
Intervention: 20 ml of hyperbaric bupivacaine 0.25% plus 1mL of placebo
Number of subjects: 50
Study 22078217 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) group treatment
Number of subjects: 21
Study 22078217 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 21
Study 20729016 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice (500 mL/d) with aerobic training (1h, 3 times a week for 3 months)
Number of subjects: 26
Study 20729016 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (1h, 3 times a week for 3 months) without orange juice
Number of subjects: 26
Study 17078440 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and cupping
Number of subjects: 80
Study 17078440 — intervention group
Group type: COMPARATOR
Intervention: Ritaline
Number of subjects: 80
Study 15333465 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous individuals carrying the Glu variant of APE1
Number of subjects: 463
Study 15333465 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for XPA (‐4A)
Number of subjects: 463
Study 15333465 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for XPD 751Gln
Number of subjects: 463
Study 15333465 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for XRCC3 241Met
Number of subjects: 463
Study 15333465 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for XPA (‐4A) in adenocarcinoma cases
Number of subjects: 463
Study 15333465 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for XRCC3 241Met in adenocarcinoma cases
Number of subjects: 463
Study 15333465 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for two or three risk alleles (XPA (‐4A) and XPD 751Gln, XRCC3‐241Met)
Number of subjects: 463
Study 11789775 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation (group I)
Number of subjects: 62
Study 11789775 — intervention group
Group type: COMPARATOR
Intervention: Control (group II)
Number of subjects: 62
Study 9182022 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC plus dexrazoxane (administered after six courses of FAC)
Number of subjects: 0
Study 9182022 — intervention group
Group type: COMPARATOR
Intervention: FAC alone
Number of subjects: 0
Study 8314510 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric enteral nutrition
Number of subjects: 32
Study 8314510 — intervention group
Group type: COMPARATOR
Intervention: Steroids (1 mg/kg/day of prednisone)
Number of subjects: 32
Study 8314510 — intervention group
Group type: COMPARATOR
Intervention: Steroids
Number of subjects: 32
Study 3438430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tasks (counting backward by 17's, Stroop task, spatial task)
Number of subjects: 65
Study 3438430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tasks
Number of subjects: 65
Study 30958316 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation treadmill training (PTT), n=21
Number of subjects: 43
Study 30958316 — intervention group
Group type: COMPARATOR
Intervention: Conventional treadmill training (CTT), n=22
Number of subjects: 43
Study 30958316 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT), n=20
Number of subjects: 43
Study 30028478 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcostal TAP block in addition to intravenous analgesic regimen (group II)
Number of subjects: 100
Study 30028478 — intervention group
Group type: COMPARATOR
Intervention: Intravenous analgesic regimen alone (group I)
Number of subjects: 100
Study 27480203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-initiated protocol for acetaminophen administration for patients with pain or fever
Number of subjects: 0
Study 27480203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-initiated protocol for troponin testing for patients with suspected ischemic chest pain
Number of subjects: 0
Study 27480203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-initiated protocol for suspected fractured hip
Number of subjects: 0
Study 27480203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-initiated protocol for vaginal bleeding during pregnancy
Number of subjects: 0
Study 25402657 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-frequency bioimpedance (MF-BIS)
Number of subjects: 35
Study 25402657 — intervention group
Group type: COMPARATOR
Intervention: Single-frequency bioimpedance (SF-BIA)
Number of subjects: 35
Study 23227682 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Shu‐stream and Ying‐spring acupoints (group A)
Number of subjects: 85
Study 23227682 — intervention group
Group type: COMPARATOR
Intervention: Routine acupoints (group B)
Number of subjects: 85
Study 20353411 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 70
Study 20353411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 18922041 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of vitamin K1 daily
Number of subjects: 440
Study 18922041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 15838417 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone administration of the Stroke Impact Scale (SIS)
Number of subjects: 458
Study 15838417 — intervention group
Group type: COMPARATOR
Intervention: Mail administration of the Stroke Impact Scale (SIS)
Number of subjects: 458
Study 14503058 — intervention group
Group type: EXPERIMENTAL
Intervention: Dandi Tablet (DDT), 4 tablets twice a day for 3 months
Number of subjects: 73
Study 14503058 — intervention group
Group type: COMPARATOR
Intervention: Nylestriol, 5 mg every month for 3 months
Number of subjects: 73
Study 10936116 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 microg once daily
Number of subjects: 330
Study 10936116 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 microg once daily
Number of subjects: 330
Study 10936116 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 microg once daily
Number of subjects: 330
Study 10936116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 9052557 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 315
Study 9052557 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 315
Study 9052557 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 315
Study 8392897 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg four times daily
Number of subjects: 69
Study 8392897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 8392897 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 69
Study 3552842 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) treatment
Number of subjects: 561
Study 3552842 — intervention group
Group type: COMPARATOR
Intervention: Control (CT) group
Number of subjects: 561
Study 29171359 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (0.9 mg/kg)
Number of subjects: 6136
Study 27764799 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric nanoparticle containing docetaxel (PNP‐DTX) at 75 mg/m2
Number of subjects: 18
Study 27764799 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric nanoparticle containing docetaxel (PNP‐DTX) at 60 mg/m2
Number of subjects: 18
Study 27764799 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric nanoparticle containing docetaxel (PNP‐DTX) at 45 mg/m2
Number of subjects: 18
Study 27764799 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric nanoparticle containing docetaxel (PNP‐DTX)
Number of subjects: 18
Study 27764799 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (DTX) at 75 mg/m2
Number of subjects: 18
Study 27764799 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (DTX)
Number of subjects: 18
Study 26631181 — intervention group
Group type: EXPERIMENTAL
Intervention: Group self-management only
Number of subjects: 0
Study 26631181 — intervention group
Group type: EXPERIMENTAL
Intervention: Group self-management plus personalised genetic- and lifestyle-associated risk information
Number of subjects: 0
Study 26631181 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 0
Study 22999654 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg testosterone
Number of subjects: 12
Study 20422942 — intervention group
Group type: EXPERIMENTAL
Intervention: New donepezil 10 mg formulation (test formulation)
Number of subjects: 0
Study 20422942 — intervention group
Group type: COMPARATOR
Intervention: Reference product
Number of subjects: 0
Study 18251114 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic dance intervention (3 sessions per week for 6 months)
Number of subjects: 151
Study 18251114 — intervention group
Group type: COMPARATOR
Intervention: Safety education (control group, 18 sessions over 6 months)
Number of subjects: 151
Study 16724375 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program for general practitioners on pain management (relationships and communication, pain evaluation, prescription, negotiation of a patient contract)
Number of subjects: 842
Study 16724375 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program for general practitioners
Number of subjects: 842
Study 16724375 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving a presentation about obtaining consent in trials
Number of subjects: 842
Study 14656913 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 280
Study 14656913 — intervention group
Group type: COMPARATOR
Intervention: Off-pump bypass surgery
Number of subjects: 280
Study 11122497 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional hazards model with random effects
Number of subjects: 0
Study 11122497 — intervention group
Group type: EXPERIMENTAL
Intervention: Markov chain Monte Carlo (MCMC) methods
Number of subjects: 0
Study 11122497 — intervention group
Group type: EXPERIMENTAL
Intervention: Louis' formula
Number of subjects: 0
Study 11122497 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior expectations and variances of individual random effects
Number of subjects: 0
Study 8649620 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose desferrioxamine (DFO) 5 mg/kg administered 5 hours prior to dialysis (group I: n = 14)
Number of subjects: 41
Study 8649620 — intervention group
Group type: COMPARATOR
Intervention: Low-dose desferrioxamine (DFO) 5 mg/kg administered in the conventional way (group II: n = 27)
Number of subjects: 41
Study 8649620 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose desferrioxamine (DFO) treatment
Number of subjects: 41
Study 1462278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mydocalm muscle relaxant
Number of subjects: 0
Study 1462278 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory complex therapy with Mydocalm
Number of subjects: 0
Study 1462278 — intervention group
Group type: COMPARATOR
Intervention: Anti-inflammatory complex therapy (control)
Number of subjects: 0
Study 6723838 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine in combination with inhaled terbutaline
Number of subjects: 22
Study 6723838 — intervention group
Group type: COMPARATOR
Intervention: Placebo/terbutaline
Number of subjects: 22
Study 31373405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 275
Study 31373405 — intervention group
Group type: COMPARATOR
Intervention: Control condition (treatment as usual)
Number of subjects: 275
Study 27371292 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate weight bearing
Number of subjects: 50
Study 27371292 — intervention group
Group type: COMPARATOR
Intervention: Delayed weight bearing (2 months)
Number of subjects: 50
Study 26124384 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 158
Study 26124384 — intervention group
Group type: COMPARATOR
Intervention: Control (no celecoxib)
Number of subjects: 158
Study 23849625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate plus formoterol (FL/F) 250/12 μg b.i.d. via dry powder inhaler (DPI)
Number of subjects: 196
Study 23849625 — intervention group
Group type: COMPARATOR
Intervention: Budesonide plus formoterol (BD/F) 400/12 μg b.i.d.
Number of subjects: 196
Study 22052266 — intervention group
Group type: EXPERIMENTAL
Intervention: Small gel-particle hyaluronic acid (SGP-HA)
Number of subjects: 20
Study 22052266 — intervention group
Group type: EXPERIMENTAL
Intervention: Large gel-particle hyaluronic acid (LGP-HA)
Number of subjects: 20
Study 22052266 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SGP-HA and LGP-HA
Number of subjects: 20
Study 19271110 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrogastrographic recording during a 30-min interdigestive and a 120-min postprandial period
Number of subjects: 11
Study 16495194 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha(1) 11.6 mg subcutaneously daily for 7 days
Number of subjects: 42
Study 16495194 — intervention group
Group type: COMPARATOR
Intervention: Saline 2 ml daily for 7 days (Control)
Number of subjects: 42
Study 16495194 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha(1)
Number of subjects: 42
Study 15736918 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with omega-3 long-chain polyunsaturated fatty acids (LC-PUFA)
Number of subjects: 0
Study 15736918 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 0
Study 15736918 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 11386491 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone 50 mg/day
Number of subjects: 121
Study 11386491 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 121
Study 11386491 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone 50 mg/day with cognitive coping skills
Number of subjects: 121
Study 11386491 — intervention group
Group type: COMPARATOR
Intervention: placebo with cognitive coping skills
Number of subjects: 121
Study 9243422 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical fitness program as an adjunct to the usual program
Number of subjects: 0
Study 9243422 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical fitness program with therapy
Number of subjects: 0
Study 8474059 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold therapy (early treatment)
Number of subjects: 23
Study 8474059 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed gold therapy (treatment after 6 months)
Number of subjects: 23
Study 8474059 — intervention group
Group type: COMPARATOR
Intervention: Control group (RA patients not receiving gold, n = 34)
Number of subjects: 23
Study 3820493 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1500 mg/d)
Number of subjects: 75
Study 3820493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 31463667 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 78
Study 31600221 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene Blue (MB) with Artesunate-Amodiaquine (AS-AQ) (15 mg/kg/day for 3 days)
Number of subjects: 100
Study 31600221 — intervention group
Group type: COMPARATOR
Intervention: Primaquine (PQ) with Artesunate-Amodiaquine (AS-AQ) (0.25 mg/kg at day 2)
Number of subjects: 100
Study 31600221 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene Blue (MB) with Artesunate-Amodiaquine (AS-AQ)
Number of subjects: 100
Study 28178004 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Jessner solution and TCA (20%-25%)
Number of subjects: 24
Study 28178004 — intervention group
Group type: COMPARATOR
Intervention: TCA (20%-25%) alone
Number of subjects: 24
Study 25920600 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cup and stem anteversion according to standard combined anteversion definitions
Number of subjects: 60
Study 25920600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cup placement within Lewinnek's 'safe zone'
Number of subjects: 60
Study 25920600 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight combined anteversion definitions
Number of subjects: 60
Study 25920600 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcome measures (HHS, HOOS, EQ-5D)
Number of subjects: 60
Study 24012086 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A and iron supplementation (group III)
Number of subjects: 445
Study 24012086 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A supplementation only (group I)
Number of subjects: 445
Study 24012086 — intervention group
Group type: COMPARATOR
Intervention: Iron supplementation only (group II)
Number of subjects: 445
Study 24012086 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (group IV)
Number of subjects: 445
Study 21865364 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (15 μg/kg bolus, 4 μg/kg · h infusion)
Number of subjects: 12
Study 21865364 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (0.12 μg/kg · min)
Number of subjects: 12
Study 21865364 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9% NaCl)
Number of subjects: 12
Study 21865364 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine vs. Saline in Lean Subjects
Number of subjects: 12
Study 21865364 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine vs. Saline in Lean Subjects
Number of subjects: 12
Study 21865364 — intervention group
Group type: COMPARATOR
Intervention: Saline in Lean Subjects
Number of subjects: 12
Study 21865364 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine vs. Saline in Obese Subjects
Number of subjects: 12
Study 21865364 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine vs. Saline in Obese Subjects
Number of subjects: 12
Study 21865364 — intervention group
Group type: COMPARATOR
Intervention: Saline in Obese Subjects
Number of subjects: 12
Study 19198709 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal ventilation catheter
Number of subjects: 60
Study 19198709 — intervention group
Group type: COMPARATOR
Intervention: Routine extubation
Number of subjects: 60
Study 17109305 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone treatment with brief physician management
Number of subjects: 16
Study 17109305 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone treatment with physician management and nurse-administered drug counseling
Number of subjects: 16
Study 17109305 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone treatment
Number of subjects: 16
Study 15230457 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with autism spectrum disorder
Number of subjects: 30
Study 15230457 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (children from a mainstream school)
Number of subjects: 30
Study 11996958 — intervention group
Group type: COMPARATOR
Intervention: CAD(+)DM(+): Apolipoprotein A-I/B ratio (1.7+/−0.4) vs Control (2.0+/−0.6), P<0.01
Number of subjects: 251
Study 11996958 — intervention group
Group type: COMPARATOR
Intervention: CAD(+)DM(-): Apolipoprotein B (96+/−24) vs Control (85+/−18), P<0.01
Number of subjects: 251
Study 11996958 — intervention group
Group type: COMPARATOR
Intervention: CAD(+)DM(+), CAD(+)DM(-)
Number of subjects: 251
Study 11996958 — intervention group
Group type: COMPARATOR
Intervention: PON activity
Number of subjects: 251
Study 9578185 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril 10 mg single dose
Number of subjects: 10
Study 9578185 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril 10 mg steady state (28 days therapy)
Number of subjects: 10
Study 9578185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7780282 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg nitroglycerin
Number of subjects: 12
Study 7780282 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine
Number of subjects: 12
Study 2501775 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin
Number of subjects: 97
Study 2501775 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mupirocin
Number of subjects: 97
Study 2501775 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 97